Table of contents
- Trial overview
- Who was studied
- What was tested in the study
- Study phase and size
- Main endpoint
- What the trial means for patients
Trial overview
The available trial of Xxb750 is a proof-of-concept and dose-finding study in patients with heart failure.[1] It was designed to test whether Xxb750 could lower NT-proBNP, a blood marker linked to heart strain, compared with placebo.[1]
Who was studied
The study focused on symptomatic patients with heart failure and LVEF below 50%.[1] LVEF means the percentage of blood the left side of the heart pumps out with each beat, so a value below 50% shows reduced pumping function.[1]
Participants were also receiving standard heart failure treatment, including ACEI or ARB, or sacubitril/valsartan.[1] This means the study looked at Xxb750 on top of usual care, not as a replacement for it.[1]
What was tested in the study
The trial compared three target dose levels of Xxb750 with placebo.[1] A placebo is a look-alike treatment that does not contain the study drug, and it helps researchers see whether any change is really due to Xxb750.[1]
The study was also built to examine the dose-response relationship.[1] This means researchers wanted to see whether different dose levels led to different effects on the study outcome.[1]
Study phase and size
This was a Phase 2 interventional trial with 740 planned participants.[1] Phase 2 studies usually look for early evidence that a treatment may work and help identify the best dose for later research.[1]
The trial status is listed as completed.[1] That means the study has finished collecting the planned data.[1]
Main endpoint
The main endpoint was the change in log NT-proBNP from baseline to Week 16.[1] Baseline means the start of the study, and Week 16 means the measurement taken after 16 weeks of follow-up.[1]
This endpoint was chosen to measure whether Xxb750 could improve a marker of heart stress over time.[1] The trial brief summary says the goal was to evaluate efficacy and dose response in symptomatic heart failure patients with LVEF under 50% who were already on standard care.[1]
What the trial means for patients
For patients, this trial is mainly about whether Xxb750 may help lower a heart failure blood marker when added to usual treatment.[1] It does not describe long-term outcomes in the source data, so the key focus here is early effectiveness and dose selection.[1]
Because the study included patients with ongoing symptoms and reduced LVEF, it was aimed at a group with clinically important heart failure.[1] The data provided do not include the final results, so the main information available is about the study design and goals.[1]
